INNOVIVA, INC. Investment Income, Interest
INNOVIVA, INC. (INVA) reported Investment Income, Interest of $189.00 thousand for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-01.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2013-08-01
- INNOVIVA, INC. investment income, interest for the quarter ending 2013-06-30 was $189.00K, a 110.00% increase year-over-year.
- INNOVIVA, INC. investment income, interest for the quarter ending 2012-09-30 was $158.00K, a 95.06% increase year-over-year.
- INNOVIVA, INC. investment income, interest for the quarter ending 2012-06-30 was $90.00K, a 23.73% decline year-over-year.
- INNOVIVA, INC. investment income, interest for the quarter ending 2011-09-30 was $81.00K, a 40.44% decline year-over-year.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month |
|---|---|---|---|
| 2013-06-30 | $189.00K 10-Q · filed 2013-08-01 | $375.00K 10-Q · filed 2013-08-01 | |
| 2012-09-30 | $158.00K 10-Q · filed 2012-10-31 | $248.00K derived: sum of 2 quarters · filed 2013-08-01 | $304.00K 10-Q · filed 2012-10-31 |
| 2012-06-30 | $90.00K 10-Q · filed 2013-08-01 | $145.00K 10-Q · filed 2013-08-01 | |
| 2011-09-30 | $81.00K 10-Q · filed 2012-10-31 | $199.00K derived: sum of 2 quarters · filed 2012-10-31 | $344.00K 10-Q · filed 2012-10-31 |
| 2011-06-30 | $118.00K 10-Q · filed 2012-08-01 | $263.00K 10-Q · filed 2012-08-01 | |
| 2010-09-30 | $136.00K 10-Q · filed 2011-11-02 | $270.00K derived: sum of 2 quarters · filed 2011-11-02 | $364.00K 10-Q · filed 2011-11-02 |
| 2010-06-30 | $134.00K 10-Q · filed 2011-08-03 | $229.00K 10-Q · filed 2011-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |